BioNTech to Host Innovation Series R&D Day on November 14, 2024

Rhea-AI Summary

BioNTech SE (Nasdaq: BNTX) has announced its upcoming Innovation Series R&D Day, scheduled for November 14, 2024, at 10:30 a.m. EST (16:30 CET) in New York City. The event will feature presentations from the company's leadership team, who will outline corporate strategy and provide updates on clinical pipeline progress.

The event will be accessible to investors, analysts, and the public through an online webcast. Presentation materials will be available on BioNTech's website, with the webcast replay remaining accessible for one year after the event.

MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.

On the day, BioNTech’s leadership team will provide an overview of the Company’s corporate strategy and clinical progress across its pipeline.

Investors, analysts and the interested public are invited to join the event online via this link.

A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company’s website for one year following the call. The public may also access the presentation slides via the “Events & Presentations” page of the Investor Relations section of the Company’s website at www.BioNTech.com. 

About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

CONTACTS

Investor Relations
Michael Horowicz
Investors@biontech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de

 

FAQ

When is BioNTech's (BNTX) Innovation Series R&D Day in 2024?

BioNTech's Innovation Series R&D Day is scheduled for Thursday, November 14, 2024, at 10:30 a.m. EST (16:30 CET) in New York City.

How can investors access BioNTech's (BNTX) R&D Day presentation materials?

Investors can access the presentation materials through the 'Events & Presentations' page in the Investor Relations section of BioNTech's website at www.BioNTech.com.

Will BioNTech's (BNTX) R&D Day 2024 be available for replay?

Yes, a replay of the webcast will be available shortly after the event and will be archived on BioNTech's website for one year.

What topics will be covered at BioNTech's (BNTX) R&D Day 2024?

The event will cover BioNTech's corporate strategy and provide updates on clinical progress across its pipeline, presented by the company's leadership team.